Open Access
Subscription or Fee Access
Nanotechnology Based Drug Delivery System for Cancer Therapy
Abstract
Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and material science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumor targeting and emphasize the challenges in cancer treatment.
Keywords
References
Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surfaces B: Biointerfaces. 2010; 75(1): 1–18.
Gonçalves C, Pereira P, Gama M. Self-assembled hydrogel nanoparticles for drug delivery applications. Materials. 2010; 3(2): 1420–1460.
Murphy EA, Majeti BK, Mukthavaram R, et al. Targeted nanogels: a versatile platform for drug delivery to tumors. Molecular Cancer Therapeutics. 2011; 10(6): 972–982.
Werengowska-Ciećwierz K, Wiśniewski M, Terzyk AP, et al. The chemistry of bioconjugation in nanoparticles-based drug delivery system. Advances in Condensed Matter Physics. 2015; 2015.
Chacko RT, Ventura J, Zhuang J, et al. Polymer nanogels: a versatile nanoscopic drug delivery platform. Advanced drug delivery reviews. 2012; 64(9): 836–851.
Noriega-Luna B, Godínez LA, Rodríguez FJ, et al. Applications of dendrimers in drug delivery agents, diagnosis, therapy, and detection. Journal of Nanomaterials. 2014; 2014: 39.
Franiak-Pietryga I, Ziemba B, Messmer B, et al. Dendrimers as Drug Nanocarriers: The future of gene therapy and targeted therapies in cancer. Dendrimers: Fundamentals and Applications. 2018; 25: 7.
Anitha P, Bhargavi J, Sravani G, et al. Recent progress of dendrimers in drug delivery for cancer therapy. International Journal of Applied Pharmaceutics. (Sep.-Oct.) 2018; 10(5): 34–42.
Sutradhar KB, Amin ML. Nanotechnology in cancer drug delivery and selective targeting. ISRN Nanotechnology. 2014.
Valle JW, Armstrong A, Newman C, et al. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Investigational New Drugs. 2011; 29(5): 1029–1037.
Ekambaram P, Sathali AH, Priyanka K. Solid lipid nanoparticles: a review. Sci. Rev. Chem. Commun. 2012; 2(1): 80–102.
Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Advanced Drug Delivery Reviews. 2008; 60(8): 876–885.
Wicki A, Witzigmann D, Balasubramanian V et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. Journal of Controlled Release. 2015; 200: 138–157.
Huang HC, Barua S, Sharma G, et al. Inorganic nanoparticles for cancer imaging and therapy. Journal of Controlled Release. 2011; 155(3): 344–357.
Vallet-Regí M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew. Chem. Int. Ed. 2007; 46: 7548–7558.
Ferris DP, Zhao YL, Khashab NM, et al. Light-operated mechanized nanoparticles. Journal of the American Chemical Society. 2009; 131(5): 1686–1688.
Tarn D, Ashley CE, Xue M, et al. Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. Accounts of Chemical Research. 2013; 46(3): 792–801.
Arap W, Pasqualini R, Montalti M, et al. Luminescent silica nanoparticles for cancer diagnosis. Current Medicinal Chemistry. 2013; 20(17): 2195–2211.
Zhang Y, Chu W, Foroushani AD, et al. New gold nanostructures for sensor applications: a review. Materials. 2014; 7: 5169–5201.
Zhang W, Wang F, Wang Y, et al. pH and near-infrared light dual-stimuli responsive drug delivery using DNA-conjugated gold nanorods for effective treatment of multidrug resistant cancer cells. Journal of Controlled Release. 2016; 232; 9–19.
Wang Y, Black KC, Luehmann H, et al. Comparison study of gold nanohexapods, nanorods, and nanocages for photothermal cancer treatment. ACS Nano. 2013; 7(3): 2068–2077.
Lohse SE, Murphy CJ. The quest for shape control: a history of gold nanorod synthesis. Chemistry of Materials. 2013; 25(8): 1250–1261.
Liu H, Lian T, Liu Y, et al. Plant-mediated synthesis of au nanoparticles: separation and identification of active biomolecule in the water extract of Cacumen Platycladi. Industrial & Engineering Chemistry Research. 2017; 56(18): 5262–5270.
Libutti SK, Paciotti GF, Byrnes AA, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clinical Cancer Research. 2010; 16(24): 6139–6149.
Sahoo NG, Bao H, Pan Y, et al. Functionalized carbon nanomaterials as nanocarriers for loading and delivery of a poorly water-soluble anticancer drug: a comparative study. Chemical Communications. 2011; 47(18): 5235–5237.
Chen G, Wang Y, Xie R, et al. Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery. Journal of Controlled Release. 2017; 259: 105–114.
Mahajan S, Patharkar A, Kuche K, et al. Functionalized carbon nanotubes as emerging delivery system for the treatment of cancer. International Journal of Pharmaceutics. 2018; 548(1): 540–558.
Sinha N, Yeow JW. Carbon nanotubes for biomedical applications. IEEE Transactions on Nanobioscience. 2005; 4(2): 180–195.
Caster JM, Patel AN, Zhang T, et al. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2017; 9(1): e1416.
Bobo D, Robinson KJ, Islam J, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharmaceutical Research. 2016; 33(10): 2373–2387.
Fang M, Peng CW, Pang DW, et al. Quantum dots for cancer research: current status, remaining issues, and future perspectives. Cancer Biology & Medicine. 2012; 9(3): 151.
Zhao MX, Zeng EZ. Application of functional quantum dot nanoparticles as fluorescence probes in cell labeling and tumor diagnostic imaging. Nanoscale Research Letters. 2015; 10(1): 171.
Matea CT, Mocan T, Tabaran F, et al. Quantum dots in imaging, drug delivery and sensor applications. International Journal of Nanomedicine. 2017; 12: 5421–5431.
Zhang H, Yee D, Wang C. Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. 2008. 83–91. Available from: Future Medicine.
Orecchioni M, Cabizza R, Bianco A, et al. Graphene as cancer theranostic tool: progress and future challenges. Theranostics. 2015; 5(7): 710–723.
de Melo‐Diogo D, Pais‐Silva C, Dias DR, et al. Strategies to improve cancer photothermal therapy mediated by nanomaterials. Advanced Healthcare Materials. 2017; 6(10): 1700073.
de Melo-Diogo D, Lima-Sousa R, Alves CG, et al. Functionalization of graphene family nanomaterials for application in cancer therapy. Colloids and Surfaces B: Biointerfaces. 2018; 171(9): 260–275.
Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release. 2010; 148(2): 135–146.
Yu BO, Tai HC, Xue W, et al. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Molecular Membrane Biology. 2010; 27(7): 286–298.
Jacobs I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the literature. Human Reproduction. 1989; 4(1): 1–12.
Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews. 2012; 64: 24–36.
Gaur U, Sahoo SK, De Tapas K, et al. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. International Journal of Pharmaceutics. 2000; 202(1–2): 1–10.
Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. Journal of Drug Targeting. 2007; 15(7–8): 457–464.
Ruoslahti E. Specialization of tumour vasculature. Nature Reviews Cancer. 2002; 2(2): 83.
Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 2002; 1(3): 219–227.
Folkman J. Fighting cancer by attacking its blood supply. Scientific American. 1996; 275(3): 150–154.
Baker CH, Fidler IJ. Tumor microenvironment and angiogenesis. Antiangiogenic Cancer Therapy. 2007; 148–165.
Kremer C, Breier G, Risau W, et al. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Research. 1997; 57(17): 3852–3859.
Liu B, Earl HM, Baban D, et al. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochemical and Biophysical Research Communications. 1995; 217(3): 721–727.
Veikkola T, Karkkainen M, Claesson-Welsh L, et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Research. 2000; 60(2): 203–212.
Backer MV, Gaynutdinov TI, Patel V, et al. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Molecular Cancer Therapeutics. 2005; 4(9): 1423–1429.
Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Advanced Drug Delivery Reviews. 2008; 60(15): 1615–1626.
Wang Z, Chui WK, Ho PC. Integrin targeted drug and gene delivery. Expert Opinion on Drug Delivery. 2010; 7(2): 159–171.
Nasongkla N, Shuai X, Ai H, et al. cRGD‐functionalized polymer micelles for targeted doxorubicin delivery. Angewandte Chemie International Edition. 2004; 43(46): 6323–6327.
Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nature Reviews Cancer. 2002; 2(2): 91.
Dienst A, Grunow A, Unruh M, et al. Specific occlusion of murine and human tumor vasculature by VCAM-1–targeted recombinant fusion proteins. Journal of the National Cancer Institute. 2005; 97(10): 733–747.
Mansour AM, Drevs J, Esser N, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Research. 2003; 63(14): 4062–4066.
Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2007; 2(12): 751–760.
Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolobeled monoclonal antibodies. Journal of Nuclear Medicine. 2005; 46(1): 115S–127S.
Suzawa T, Nagamura S, Saito H, et al. Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly (ethylene glycol)-based cleavable linker. Journal of Controlled Release. 2002; 79(1–3): 229–242.
Abou-Jawde R, Choueiri T, Alemany C, et al. An overview of targeted treatments in cancer. Clinical Therapeutics. 2003; 25(8): 2121–2137.
Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treatment Reviews. 2004; 30(1): 1–17.
Nicholson RI, Gee JM W, Harper M. EGFR and cancer prognosis. European Journal of Cancer. 2001; 37: 9–15.
Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplification‐rearrangement in human glioblastomas. International Journal of Cancer. 1995; 62(2): 145–148.
Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. Journal of Clinical Oncology. 2003; 21(14): 2787–2799.
Nobs L, Buchegger F, Gurny R, et al. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjugate Chemistry. 2006; 17(1): 139–145.
Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2–positive breast cancer. Journal of Clinical Oncology. 2009; 27(34): 5838–5847.
Wartlick H, Michaelis K, Balthasar S, et al. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. Journal of Drug Targeting. 2004; 12(7): 461–471.
Daniels TR, Bernabeu E, Rodríguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochimica et Biophysica Acta (BBA)-General Subjects. 2012; 1820(3): 291–317.
Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferrin‐conjugated paclitaxel‐loaded nanoparticles in a murine model of prostate cancer. International Journal of Cancer. 2004; 112(2): 335–340.
Faulk WP, Taylor CG, Yeh CJ, et al. Preliminary clinical study of transferrin-adriamycin conjugate for drug delivery to acute leukemia patients. Molecular Biotherapy. 1990; 2(1): 57–60.
Lee JM, Yoon TJ, Cho YS. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. BioMed Research International. 2013; 2013.
Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. Journal of Pharmaceutical Sciences. 2005; 94(10): 2135–2146.
Kukowska-Latallo JF, Candido KA, Cao Z, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Research. 2005; 65(12): 5317–5324.
Ratnam M, Hao H, Zheng X, et al. Receptor induction and targeted drug delivery: a new antileukaemia strategy. Expert Opinion on Biological Therapy. 2003; 3(4): 563–574.
Wang H, Zheng L, Peng C, et al. Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adencarcinoma. Biomaterials. 2013; 34(2): 470–480.
Chen TJ, Cheng TH, Hung YC, et al. Targeted folic acid‐PEG nanoparticles for noninvasive imaging of folate receptor by MRI. Journal of Biomedical Materials Research Part A: An Official Journal of the Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials. 2008; 87(1): 165–175.
Ni X, Castanares M, Mukherjee A, et al. Nucleic acid aptamers: clinical applications and promising new horizons. Current Medicinal Chemistry. 2011; 18(27): 4206–4214.
Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Research. 2004; 64(21): 7668–7672.
Ko HY, Lee JH, Kang H, et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. Journal of Nuclear Medicine. 2010; 51(1): 98–105.
Warenius HM, Galfre G, Bleehen NM, et al. Attempted targeting of a monoclonal antibody in a human tumour xenograft system. European Journal of Cancer and Clinical Oncology. 1981; 17(9): 1009–1015.
Mehren MV, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annual Review of Medicine. 2003; 54(1): 343–369.
Albanell J, Baselga J Trastuzumab. A humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today (Barc). 1999; 35(12): 931–946.
Singh S, Kumar NK, Dwiwedi P, et al. Monoclonal antibodies: a review. Current Clinical Pharmacology. 2018; 13(2): 85–99.
Porkka K, Laakkonen P, Hoffman JA, et al. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proceedings of the National Academy of Sciences. USA. 2002, May 28. 99(11): 7444–7449.
Kelly KA, Jones DA. Isolation of a colon tumor specific binding peptide using phage display selection. Neoplasia. 2003; 5(5): 437–444.
Ross JS, Gerald P Linette, James Stec, et al. Breast cancer biomarkers and molecular medicine. Expert Rev. Mol. Diagn. 2003; 3(5): 573–585.
HC Wu, DK Chang, CT Huang. Targeted therapy for cancer. Journal of Cancer Molecules. 2006; 2(2): 57–66.
RK Jain. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology. 2005; 19(4): 7–16.
Desai N. Nanoparticle albumin-bound paclitaxel (Abraxane®). In: Otagiri M, Chuang V. (eds). Albumin in Medicine. Singapore: Springer; 2016. pp. 101–119.
Lee KS, Chung HC, Im SA, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Research and Treatment. 2008 Mar 1; 108(2): 241–250.
Terwogt JM, ten Bokkel Huinink WW, Schellens JH, et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs. 2001 Apr 1; 12(4): 315–323.
Bedikian AY, DeConti RC, Conry R, et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Annals of Oncology. 2010 Sep 20; 22(4): 787–793.
Roby KF , Niu F Rajewski RA, et al., Syngeneic Mouse Model of Epithelial Ovarian Cancer: Effects of Nanoparticulate Paclitaxel, Nanotax®. In: Coukos G., Berchuck A., Ozols R. (eds) Ovarian Cancer. Advances in Experimental Medicine and Biology, 2008; vol 622: 169-181
Langer CJ, O’Byrne KJ, Socinski MA, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. Journal of Thoracic Oncology. 2008; Jun 1; 3(6): 623–630.
Awada A, Bondarenko IN, Bonneterre J, et al. A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Annals of Oncology. 2014 Apr 1; 25(4): 824–831.
Slingerland M, Guchelaar HJ, Rosing H, et al. Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. Clinical Therapeutics. 2013 Dec 1; 35(12): 1946–1954.
Xu X, Wang L, Xu HQ, et al. Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pacific Journal of Cancer Prevention. 2013; 14(4): 2591–2594.
Vergote I, Brize A, Lisyanskaya AS, et al. Randomized phase III study comparing paclical-carboplatin with paclitaxel-carboplatin in patients with recurrent platinum-sensitive epithelial ovarian cancer. Journal of Clinical Oncology. 2015; 5517–5517
Kato K, Chin K, Yoshikawa T, et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Investigational New Drugs. 2012 Aug 1; 30(4): 1621–1627.
Madaan A, Singh P, Awasthi A, et al. Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel TM. Clinical and Translational Oncology. 2013 Jan 1; 15(1): 26–32.
Hu Z, Luo F, Pan Y, et al. Arg‐Gly‐Asp (RGD) peptide conjugated poly (lactic acid)–poly (ethylene oxide) micelle for targeted drug delivery. Journal of Biomedical Materials Research Part A: An Official Journal of the Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials. 2008 Jun 1; 85(3): 797–807.
Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Journal of Clinical Oncology. 1997 Mar; 15(3): 987–993.
Khemapech N, Oranratanaphan S, Termrungruanglert W, et al. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®). Asian Pacific Journal of Cancer Prevention. 2013; 14(3): 2131–2135.
Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Journal of Clinical Oncology. 2001 Mar 1; 19(5): 1444–1454.
Dou Y, Hynynen K, Allen C. To heat or not to heat: challenges with clinical translation of thermosensitive liposomes. Journal of Controlled Release. 2017 Mar 10; 249: 63–73.
Mamot C, Ritschard R, Wicki A, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. The Lancet Oncology. 2012; Dec 1; 13(12): 1234–1241.
Barraud L, Merle P, Soma E, Lefrançois L, et al. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. Journal of Hepatology. 2005 May 1; 42(5): 736–743.
Pitto-Barry A, Barry NP. Pluronic® block-copolymers in medicine: from chemical and biological versatility to rationalisation and clinical advances. Polymer Chemistry. 2014; 5(10): 3291–3297.
Owen SC, Chan DP, Shoichet MS. Polymeric micelle stability. Nano Today. 2012 Feb 1; 7(1): 53–65.
Matsumura Y, Gotoh M, Muro K, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Annals of Oncology. 2004 Mar 1; 15(3): 517–525.
Pawar SK, Vavia P. Efficacy interactions of PEG–DOX–N-acetyl glucosamine prodrug conjugate for anticancer therapy. European Journal of Pharmaceutics and Biopharmaceutics. 2015 Nov 1; 97: 454–463.
Yang J, Cho EJ, Seo S, et al. Enhancement of cellular binding efficiency and cytotoxicity using polyethylene glycol base triblock copolymeric nanoparticles for targeted drug delivery. Journal of Biomedical Materials Research Part A: An Official Journal of the Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials. 2008 Jan; 84(1): 273–280.
Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. Journal of Controlled Release. 2004 Apr 28; 96(2): 273–283.
Jang E, Lim EK, Choi Y, Kim E, Kim HO, Kim DJ, Suh JS, Huh YM, Haam S. π-Hyaluronan nanocarriers for CD44-targeted and pH-boosted aromatic drug delivery. Journal of Materials Chemistry B. 2013; 1(41): 5686–5693.
Eliaz RE, Nir S, Marty C, Szoka FC. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Research. 2004 Jan 15; 64(2): 711–718.
Lim EK, Huh YM, Yang J, et al. pH‐triggered drug‐releasing magnetic nanoparticles for cancer therapy guided by molecular imaging by MRI. Advanced Materials. 2011 Jun 3; 23(21): 2436–2442.
Phan VN, Lim EK, Kim T, et al. A highly crystalline manganese‐doped iron oxide nanocontainer with predesigned void volume and shape for theranostic applications. Advanced Materials. 2013 Jun 18; 25(23): 3202–3208.
Laginha KM, Moase EH, Yu N, et al. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer. Journal of Drug Targeting. 2008 Jan 1; 16(7–8): 605–610.
Yang J, Lee J, Kang J, et al. Smart drug‐loaded polymer gold nanoshells for systemic and localized therapy of human epithelial cancer. Advanced Materials. 2009 Nov 20; 21(43): 4339–4342.
Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Research. 2005 Dec 15; 65(24): 11631–11638.
Fens MH, Hill KJ, Issa J, et al. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16. F10 melanoma. British Journal of Cancer. 2008 Oct; 99(8): 1256.
Murphy EA, Majeti BK, Barnes LA, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proceedings of the National Academy of Sciences. 2008 Jul 8; 105(27): 9343–9348.
Kim E, Jung Y, Choi H, et al. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials. 2010 Jun 1; 31(16): 4592–4599.
Danhauser-Riedl S, Hausmann E, Schick HD, et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Investigational New Drugs. 1993 Jun 1; 11(2–3): 187–195.
Seymour LW, Ferry DR, Kerr DJ, et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. International Journal of Oncology. 2009 Jun 1; 34(6): 1629–1636.
Hopewell JW, Duncan R, Wilding D, et al. Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent. Human & Experimental Toxicology. 2001 Sep; 20(9): 461–470.
Forssen EA, Ross ME. Daunoxome® treatment of solid tumors: preclinical and clinical investigations. Journal of Liposome Research. 1994 Jan 1; 4(1): 481–512.
Rodriguez MA, Pytlik R, Kozak T, et al. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2009 Aug 1; 115(15): 3475–3482.
Glantz MJ, Jaeckle KA, Chamberlain MC, Phupanich S, Recht L, Swinnen, LJ, Maria B, LaFollette S, Schumann G, Cole B, Howell S, 1999. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 1999; 5(11): 3394–3402.
Venkatakrishnan K, Liu Y, Noe D, et al. Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment. British Journal of Clinical Pharmacology. 2014 Jun; 77(6): 998–1010.
Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Advanced Drug Delivery Reviews. 2001 Mar 1; 46(1–3):169–185.
Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncaspar®) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007 Aug 1; 12(8): 991–998.
Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. Journal of Clinical Oncology. 2012 Jun 20; 30(18): 2183–2189.
Burris III HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast cancer after prior HER2-directed therapy. Journal of Clinical Oncology. 2010 Dec 20; 29(4): 398–405.
Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Molecular Pharmaceutics. 2009 Apr 3; 6(3): 659–668.
Izbicka E, Diaz A, Campos D, et al. Evaluation of antitumor activity and biomarkers for MBP-426 in human pancreatic cancer xenograft models in vivo. American Association for Cancer Research. 2007.
Nowotnik DP, Cvitkovic E. ProLindac™ (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Advanced Drug Delivery Reviews. 2009 Nov 12; 61(13): 1214–1219.
Plummer R, Wilson RH, Calvert H, et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. British Journal of Cancer. 2011 Feb; 104(4): 593–598.
Lin X, Zhang Q, Rice JR, et al. Improved targeting of platinum chemotherapeutics: the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. European Journal of Cancer. 2004 Jan 1; 40(2): 291–297.
Lu C, Perez-Soler R, Piperdi B, et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. Journal of Clinical Oncology. 2005 May 20; 23(15): 3495–3501.
Seetharamu N, Kim E, Hochster H, et al. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Research. 2010 Feb 1; 30(2): 541–545.
de Jonge MJ, Slingerland M, Loos WJ, et al. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. European Journal of Cancer. 2010 Nov 1; 46(16): 3016–3021.
Jehn CF, Boulikas T, Kourvetaris A, et al. First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). Anticancer Research. 2008 Nov 1; 28(6B): 3961–3964.
Refbacks
- There are currently no refbacks.